Figure 3
From: Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro
Simulated probenecid concentrations. A population pharmacokinetic model was used to generate probenecid exposure profiles comparing (A) 600 mg twice daily, 900 mg twice daily, or (B) 1800 mg once daily administration for 20 days. The IC90 level corrected for 95% protein binding is 2.08 µg/ml (shown as dashed line). All doses provided exposures well over the IC90 level at all time points. Figures were prepared using GraphPad Prism, v9.2, https://www.graphpad.com/updates/.
